SCM
SPRY icon

Soleus Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Soleus Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,000
Closed -$567K – 100
2023
Q3 		$567K Buy
+150,000
New +$985K 0.05% 87
2021
Q3 		– Sell
-31,306
Closed -$967K – 83
2021
Q2 		$967K Sell
31,306
-65,950
-68% -$2.11M 0.15% 59
2021
Q1 		$4.24M Sell
97,256
-10,570
-10% -$500K 0.76% 23
2020
Q4 		$5M Buy
+107,826
New +$3.6M 0.66% 20

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Soleus Capital Management's SPRY Position: Q4 2023 in Review

Soleus Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2023, closing a stake of 150,000 shares — an estimated $567K sold.

Soleus Capital Management first reported a position in SPRY in Q4 2020 and held it in 4 quarters. The position peaked at $5M in Q4 2020. 100 funds tracked by Wall St. Rank hold SPRY as of Q4 2023.

  • Soleus Capital Management reported no remaining ARS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 150,000 ARS Pharmaceuticals shares in Q4 2023, an estimated $567K.
  • Soleus Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Soleus Capital Management's ARS Pharmaceuticals position peaked at $5M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.